Amarin Corporation plc · NASDAQ:AMRN
Amarin — Q3 2023 Earnings Presentation
15 slides from Amarin's earnings presentation, Nov 1, 2023
Slide 1: Third Quarter 2023 Financial Results and Business Update
Third Quarter 2023 Financial Results and Business Update Conference Call Patrick Holt President & CEO Tom Reilly CFO November 1, 2023
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (VAZKEPA® in Europe), clinical and regulatory efforts and timelines, potential regulatory and pricing approvals, generic product launches, res
Slide 3: Today's Agenda
Today’s Agenda 01 Third Quarter 2023 Business Update Patrick Holt, President & CEO 02 Third Quarter 2023 Financial Results Tom Reilly, CFO 03 Looking Ahead to the Remainder of 2023 & 2024 Patrick Holt, President & CEO AMARIN, VASCEPA, VAZKEPA and REDUCE-IT are trademarks of Amarin Pharmaceuticals Ir
Slide 4: Third Quarter 2023 Business Update
01 THIRD QUARTER 2023 BUSINESS UPDATE Patrick Holt, President & CEO
Slide 5: Focus on Operational Momentum
FOCUS ON OPERATIONAL MOMENTUM EUROPE U.S. RoW Extend Product Maximize Patient Accelerate European Lifecycle and Uptake via Revenue and P&R Drive Profit Partnerships Outcomes CONTINUE CASH PRESERVATION 5
Slide 6: Europe: New Leadership Driving Early Commercial & Ongoing Pricing & Reimbursement Progress
EUROPE: NEW LEADERSHIP DRIVING EARLY COMMERCIAL & ONGOING PRICING & REIMBURSEMENT PROGRESS European Commercial Updates UK (England, Wales Double-digit growth in demand from England/Wales; Ongoing access to formularies in Scotland. & Scotland) Spain Promising initial sales across regions; Commercial
Slide 7: U.S.: Three Years Post-Generic, Branded Vascepa Remains Market Leader Driving Profit
7 U.S.: THREE YEARS POST-GENERIC, BRANDED VASCEPA REMAINS MARKET LEADER DRIVING PROFIT Total IPE Norm TRx Trend NOVEMBER 2020 JUNE 2021 JANUARY 2022 DECEMBER 2022 Hikma launches icosapent ethyl capsules; DRL launches icosapent Apotex launches icosapent Teva launches icosapent first generic Vascepa®
Slide 8: RoW: Partners Are Bringing Vascepa/Vazkepa to More Patients Globally
ROW: PARTNERS ARE BRINGING VASCEPA/VAZKEPA TO MORE PATIENTS GLOBALLY China Launched in October 2023 (VHTG) Canada Israel (Neopharm) Hong Kong Launched in Approved Approved February 2020 March 2023 February 2022 Launched South Korea and ASEAN (Lotus) Regulatory Approval Approval Processes A
Slide 9: Third Quarter 2023 Financial Results and 2023 Guidance
02 THIRD QUARTER 2023 FINANCIAL RESULTS AND 2023 GUIDANCE Tom Reilly, CFO
Slide 10: Managing Operating Expenses to Maximize Profitability Amid Revenue Pressure
MANAGING OPERATING EXPENSES TO MAXIMIZE PROFITABILITY AMID REVENUE PRESSURE Total Net Revenue Total Operating Expense $M U.S. Revenue Remained Flat (excluding Stock Comp, Restructuring & Advisory Fees) Despite Generic Market 300 $279M -$61M • 3Q 2023 total net revenues remained flat 300 at $66 milli
Slide 11: Continued Focus on Controlling Costs and Maximizing Cash
CONTINUED FOCUS ON CONTROLLING COSTS AND MAXIMIZING CASH 325 Strong Cash Position; Five Consecutive +$8M Quarters of Positive Cash Flow $321M Third Quarter 2023 320 Cash Positive ~$8M • Cash balance at 9/30/2023 +$8M approximately $321M; $15M+ versus Q3 2022 315 +$5M $313M • Expense reductions and t
Slide 12: Looking Ahead to the Remainder of 2023 & Early 2024
03 LOOKING AHEAD TO THE REMAINDER OF 2023 & EARLY 2024 Patrick Holt, President & CEO
Slide 13: Focus on Operational Momentum
FOCUS ON OPERATIONAL MOMENTUM EUROPE U.S. RoW Extend Product Maximize Patient Accelerate European Lifecycle and Drive Revenue and P&R Uptake via Profit Outcomes Partnerships CONTINUE CASH PRESERVATION 13
Slide 14: Q&A
Q&A
Slide 15: Thank You
Vascepa Vazkepa (icosapent ethyl) (icosapent ethyl) THANK YOU